The global NGS-based proteomics services market was valued at USD 412.6 million in 2025. It is estimated at USD 478.9 million in 2026 and is projected to reach USD 1.84 billion by 2036, at a CAGR of 14.4% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering population-scale proteomics, pharmaceutical demand for target and biomarker data, affinity assay and sequencing technologies, quality and data governance requirements, pricing and cost per sample, the service provider landscape, and future growth opportunities.
The market covers outsourced assay, data production, and bioinformatics work in which next-generation sequencing serves as the readout for protein levels. In these methods, antibody pairs, aptamers, or oligonucleotide-tagged antibodies bind their target proteins, and each binding event is turned into a DNA barcode that a sequencer counts. Services in scope are built on proximity extension assays, sequencing-read aptamer assays, NULISA (nucleic acid-linked immuno-sandwich assay) technology, and oligonucleotide-conjugated antibodies for single-cell and spatial proteogenomics, and include study design, sample processing, sequencing, quality control, and data analysis. Sales of instruments, kits, and reagents for in-house use, mass spectrometry-based proteomics services, and immunoassay services without a sequencing readout are excluded.
Sequencing readouts make it possible to quantify thousands of proteins from a few microliters of plasma in very large cohorts, which conventional immunoassays and mass spectrometry struggle to do. According to UK Biobank, its Pharma Proteomics Project, run with 14 biopharmaceutical companies on Thermo Fisher Scientific's Olink Explore platform, is measuring more than 5,400 proteins in up to 600,000 samples, with data releases starting in 2026 and the full dataset due in 2027. A 2023 pilot of more than 54,000 UK Biobank samples, published in Nature, has been cited more than 400 times, and Illumina Protein Prep, which reads up to 9,500 human protein targets in one experiment, has been used by Genomics England on more than 7,800 rare disease participants.
Large studies remain expensive, particularly for panels covering thousands of proteins; according to UK Biobank, extra funding was sought to extend its project from 300,000 to 600,000 samples, and such costs limit use by academic groups, smaller biotechnology firms, and institutions in emerging economies. Each technology relies on its own affinity reagents and covers a partly different set of proteins, and the lack of common reference materials, formats, and normalization methods makes datasets hard to combine. Kits sold for in-house use, including Olink Reveal and Illumina Protein Prep, let laboratories with sequencers run assays in-house, which shifts some routine work away from service providers, and mass spectrometry competes for studies that need protein isoforms and modifications.
Combined analysis of protein and genomic data is a major opportunity, as sequencing-based protein data fit into the same bioinformatics tools, such as DRAGEN and Illumina Connected Multiomics, and integrated study design and interpretation earn more than sample processing alone. Clinical trial proteomics for pharmacodynamic and companion biomarker work, new national biobanks in Asia-Pacific and the Middle East, and single-cell and spatial proteogenomics offer further openings. Key trends include consolidation around large tools companies, the growth of population-scale protein datasets, and a strong focus on blood-based biomarkers for neurodegenerative disease.
By technology, the NGS-based proteomics services market is segmented into proximity extension assay (PEA), aptamer-based assays, NULISA, antibody-oligonucleotide conjugate-based single-cell & spatial proteogenomics, and other technologies. Proximity extension assays are expected to hold the largest share in 2026, owing to wide use of the Olink platform among drug developers, universities, and contract laboratories, its selection for the UK Biobank project, and its availability through providers such as Novogene and Azenta Life Sciences. NULISA is set to record the highest CAGR, as it detects low-abundance proteins with high sensitivity, it is being widely adopted in neurodegenerative disease research, and Alamar Biosciences reported 82% revenue growth in the second quarter of 2026. Aptamer-based assays are also expected to grow strongly after Illumina completed its acquisition of SomaLogic in January 2026 and made Illumina Protein Prep more widely available.
By service type, the NGS-based proteomics services market is segmented into sample processing & assay services, data analysis & bioinformatics services, and study design & consulting services. Sample processing & assay services are expected to account for the largest share in 2026, since every study depends on sample preparation, the affinity assay, library preparation, sequencing, and quality control, and large biobank and pharmaceutical projects run these steps at high volume. Data analysis & bioinformatics services are set to grow at the highest CAGR, driven by ever larger and more complex datasets, the need to link protein levels with genetics and clinical outcomes, and the move of some routine assay work into in-house laboratories using distributed kits. Study design & consulting services benefit from client interest in integrated multiomics study planning and interpretation.
By application, the NGS-based proteomics services market is segmented into drug discovery & development, biomarker discovery & validation, population health & biobank studies, disease research (neurology, oncology, inflammation & immunology, cardiometabolic diseases, and other diseases), and clinical research. Drug discovery & development is expected to hold the largest share in 2026, as pharmaceutical companies rely on high-plex protein data for target identification, mechanism studies, and trial biomarker analysis, reflected in the 14 drug makers funding the UK Biobank project. Population health & biobank studies are set to grow the fastest, given the scale of the UK Biobank study and the rising number of national biobanks adding protein data to genomic resources. Within disease research, neurology is expected to grow the fastest on demand for blood-based biomarkers, while oncology and inflammation & immunology hold significant shares.
By end user, the NGS-based proteomics services market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, biobanks & population health programs, contract research organizations, and hospitals & clinical research centers. In 2026, pharmaceutical & biotechnology companies are expected to lead, as they outsource large protein studies to reach high-plex platforms, sample capacity, and specialist skills without investing in equipment. Biobanks & population health programs are set to record the highest CAGR, supported by population-scale studies in the U.K. and the expansion of national genomic medicine programs elsewhere. Academic and research institutes remain important users, often through core facilities such as Sweden's National Genomics Infrastructure.
In 2026, North America is expected to lead the global NGS-based proteomics services market, owing to its concentration of pharmaceutical and biotechnology companies, high research spending, strong academic and translational centers, and the presence of Thermo Fisher Scientific, Illumina, and Alamar Biosciences. Large U.S. research programs in neurodegenerative disease, oncology, and immunology, backed by public and philanthropic funding, add to demand, and Canada contributes through academic centers and biotechnology clusters. Europe holds a significant share, with the U.K. as the largest country market because of UK Biobank and Genomics England, Sweden as the original home of Olink with a strong proteomics base, and Germany, France, Switzerland, and the Netherlands adding demand through pharmaceutical and academic research.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, driven by expanding pharmaceutical research, national biobank and genomic medicine programs, and large genomics service providers such as Novogene, which runs Olink Explore HT services in its laboratories. China is expected to hold the largest share in the region, backed by large research populations and precision medicine investment, with strong growth also expected in Japan, South Korea, Singapore, and Australia, and India is emerging on the back of biotechnology and contract research growth. Latin America and the Middle East & Africa hold smaller shares, with genomics programs in Saudi Arabia, the UAE, and Qatar and clinical research in Brazil and Mexico supporting demand.
The NGS-based proteomics services market is led by a small number of platform owners that run their own service laboratories, alongside genomics and contract research providers and academic core facilities that use these platforms. Providers compete on protein coverage, sensitivity, data quality, throughput, turnaround time, cost per sample, bioinformatics, and global laboratory reach. Thermo Fisher Scientific's purchase of Olink in July 2024 and Illumina's acquisition of SomaLogic in January 2026 placed the two leading high-plex affinity technologies inside major tools companies. Alamar Biosciences completed its initial public offering in April 2026 and launched the NULISAseq Immune 340 Panel and an eMTBR-tau assay in the second quarter, while Azenta Life Sciences offers Olink and NULISA services through GENEWIZ.
Key companies profiled in the report include Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Alamar Biosciences, Inc. (U.S.), Novogene Co., Ltd. (China), and Azenta, Inc. (U.S.).
The market covers outsourced assay, data production, and bioinformatics work in which next-generation sequencing serves as the readout for protein levels. In these methods, antibody pairs, aptamers, or oligonucleotide-tagged antibodies bind their target proteins, and each binding event is turned into a DNA barcode that a sequencer counts. Services in scope are built on proximity extension assays, sequencing-read aptamer assays, NULISA (nucleic acid-linked immuno-sandwich assay) technology, and oligonucleotide-conjugated antibodies for single-cell and spatial proteogenomics, and include study design, sample processing, sequencing, quality control, and data analysis. Sales of instruments, kits, and reagents for in-house use, mass spectrometry-based proteomics services, and immunoassay services without a sequencing readout are excluded.
Sequencing readouts make it possible to quantify thousands of proteins from a few microliters of plasma in very large cohorts, which conventional immunoassays and mass spectrometry struggle to do. According to UK Biobank, its Pharma Proteomics Project, run with 14 biopharmaceutical companies on Thermo Fisher Scientific's Olink Explore platform, is measuring more than 5,400 proteins in up to 600,000 samples, with data releases starting in 2026 and the full dataset due in 2027. A 2023 pilot of more than 54,000 UK Biobank samples, published in Nature, has been cited more than 400 times, and Illumina Protein Prep, which reads up to 9,500 human protein targets in one experiment, has been used by Genomics England on more than 7,800 rare disease participants.
Market Dynamics
Population-scale proteomics is the main driver of the NGS-based proteomics services market, as biobanks and national health programs add protein data to genetic and health records and need hundreds of thousands of samples processed under the same conditions, which favors large central service laboratories. Drug developers are a second driver: they use high-plex protein data to find and validate targets, study mechanism of action, stratify patients, and track pharmacodynamic effects, and they usually outsource this work to gain capacity without capital spending. Larger panels, higher sensitivity, and the falling cost of sequencing are lowering the cost per sample, while biomarker research in neurology, oncology, immunology, and cardiometabolic disease is widening demand; Alamar Biosciences and the AD Data Initiative have built a combined dataset of more than 140,000 samples.Large studies remain expensive, particularly for panels covering thousands of proteins; according to UK Biobank, extra funding was sought to extend its project from 300,000 to 600,000 samples, and such costs limit use by academic groups, smaller biotechnology firms, and institutions in emerging economies. Each technology relies on its own affinity reagents and covers a partly different set of proteins, and the lack of common reference materials, formats, and normalization methods makes datasets hard to combine. Kits sold for in-house use, including Olink Reveal and Illumina Protein Prep, let laboratories with sequencers run assays in-house, which shifts some routine work away from service providers, and mass spectrometry competes for studies that need protein isoforms and modifications.
Combined analysis of protein and genomic data is a major opportunity, as sequencing-based protein data fit into the same bioinformatics tools, such as DRAGEN and Illumina Connected Multiomics, and integrated study design and interpretation earn more than sample processing alone. Clinical trial proteomics for pharmacodynamic and companion biomarker work, new national biobanks in Asia-Pacific and the Middle East, and single-cell and spatial proteogenomics offer further openings. Key trends include consolidation around large tools companies, the growth of population-scale protein datasets, and a strong focus on blood-based biomarkers for neurodegenerative disease.
Segment Analysis
The report analyzes the market by technology, service type, application, end user, and geography, helping stakeholders identify the most attractive areas for service expansion, partnering, and investment.By technology, the NGS-based proteomics services market is segmented into proximity extension assay (PEA), aptamer-based assays, NULISA, antibody-oligonucleotide conjugate-based single-cell & spatial proteogenomics, and other technologies. Proximity extension assays are expected to hold the largest share in 2026, owing to wide use of the Olink platform among drug developers, universities, and contract laboratories, its selection for the UK Biobank project, and its availability through providers such as Novogene and Azenta Life Sciences. NULISA is set to record the highest CAGR, as it detects low-abundance proteins with high sensitivity, it is being widely adopted in neurodegenerative disease research, and Alamar Biosciences reported 82% revenue growth in the second quarter of 2026. Aptamer-based assays are also expected to grow strongly after Illumina completed its acquisition of SomaLogic in January 2026 and made Illumina Protein Prep more widely available.
By service type, the NGS-based proteomics services market is segmented into sample processing & assay services, data analysis & bioinformatics services, and study design & consulting services. Sample processing & assay services are expected to account for the largest share in 2026, since every study depends on sample preparation, the affinity assay, library preparation, sequencing, and quality control, and large biobank and pharmaceutical projects run these steps at high volume. Data analysis & bioinformatics services are set to grow at the highest CAGR, driven by ever larger and more complex datasets, the need to link protein levels with genetics and clinical outcomes, and the move of some routine assay work into in-house laboratories using distributed kits. Study design & consulting services benefit from client interest in integrated multiomics study planning and interpretation.
By application, the NGS-based proteomics services market is segmented into drug discovery & development, biomarker discovery & validation, population health & biobank studies, disease research (neurology, oncology, inflammation & immunology, cardiometabolic diseases, and other diseases), and clinical research. Drug discovery & development is expected to hold the largest share in 2026, as pharmaceutical companies rely on high-plex protein data for target identification, mechanism studies, and trial biomarker analysis, reflected in the 14 drug makers funding the UK Biobank project. Population health & biobank studies are set to grow the fastest, given the scale of the UK Biobank study and the rising number of national biobanks adding protein data to genomic resources. Within disease research, neurology is expected to grow the fastest on demand for blood-based biomarkers, while oncology and inflammation & immunology hold significant shares.
By end user, the NGS-based proteomics services market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, biobanks & population health programs, contract research organizations, and hospitals & clinical research centers. In 2026, pharmaceutical & biotechnology companies are expected to lead, as they outsource large protein studies to reach high-plex platforms, sample capacity, and specialist skills without investing in equipment. Biobanks & population health programs are set to record the highest CAGR, supported by population-scale studies in the U.K. and the expansion of national genomic medicine programs elsewhere. Academic and research institutes remain important users, often through core facilities such as Sweden's National Genomics Infrastructure.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 19 countries and four rest-of-region groups. The regional analysis of the NGS-based proteomics services market considers pharmaceutical research activity, biobank and population health programs, research funding, laboratory capacity, and data privacy and biobank access rules.In 2026, North America is expected to lead the global NGS-based proteomics services market, owing to its concentration of pharmaceutical and biotechnology companies, high research spending, strong academic and translational centers, and the presence of Thermo Fisher Scientific, Illumina, and Alamar Biosciences. Large U.S. research programs in neurodegenerative disease, oncology, and immunology, backed by public and philanthropic funding, add to demand, and Canada contributes through academic centers and biotechnology clusters. Europe holds a significant share, with the U.K. as the largest country market because of UK Biobank and Genomics England, Sweden as the original home of Olink with a strong proteomics base, and Germany, France, Switzerland, and the Netherlands adding demand through pharmaceutical and academic research.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, driven by expanding pharmaceutical research, national biobank and genomic medicine programs, and large genomics service providers such as Novogene, which runs Olink Explore HT services in its laboratories. China is expected to hold the largest share in the region, backed by large research populations and precision medicine investment, with strong growth also expected in Japan, South Korea, Singapore, and Australia, and India is emerging on the back of biotechnology and contract research growth. Latin America and the Middle East & Africa hold smaller shares, with genomics programs in Saudi Arabia, the UAE, and Qatar and clinical research in Brazil and Mexico supporting demand.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard with market leaders, market differentiators, vanguards, and emerging players, and market share/rank analysis by key player for 2025. Company profiles include business overviews, financial performance, product and service portfolios, strategic developments, and SWOT analyses.The NGS-based proteomics services market is led by a small number of platform owners that run their own service laboratories, alongside genomics and contract research providers and academic core facilities that use these platforms. Providers compete on protein coverage, sensitivity, data quality, throughput, turnaround time, cost per sample, bioinformatics, and global laboratory reach. Thermo Fisher Scientific's purchase of Olink in July 2024 and Illumina's acquisition of SomaLogic in January 2026 placed the two leading high-plex affinity technologies inside major tools companies. Alamar Biosciences completed its initial public offering in April 2026 and launched the NULISAseq Immune 340 Panel and an eMTBR-tau assay in the second quarter, while Azenta Life Sciences offers Olink and NULISA services through GENEWIZ.
Key companies profiled in the report include Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Alamar Biosciences, Inc. (U.S.), Novogene Co., Ltd. (China), and Azenta, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global NGS-based proteomics services market.
- Explains how biobank programs, pharmaceutical outsourcing, and multiomics research are shaping demand for sequencing-based protein services.
- Assesses the impact of study costs, limited cross-platform comparability, distributed kits, and mass spectrometry competition.
- Identifies high-growth opportunities across technology, service type, application, end user, and region.
- Tracks proximity extension, aptamer, NULISA, and single-cell proteogenomic technologies and their service availability.
- Benchmarks leading providers by panel size, sensitivity, throughput, cost per sample, bioinformatics, and laboratory reach.
- Supports service expansion, partnering, acquisition screening, and market entry decisions for platform owners, genomics service companies, contract research organizations, and investors.
Key Questions Answered
- How big is the global NGS-based proteomics services market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How are population-scale programs such as the UK Biobank Pharma Proteomics Project changing demand for services?
- Which technology, service type, application, and end-user segments will grow the fastest?
- How will distributed kits for in-house use affect service providers and their business models?
- How is NULISA changing biomarker research in neurodegenerative disease?
- What role will combined protein and genomic data analysis play in future service revenue?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading providers, and how have acquisitions changed the competitive landscape?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. NGS-Based Proteomics Services Market, by Technology
6. NGS-Based Proteomics Services Market, by Service Type
7. NGS-Based Proteomics Services Market, by Application
8. NGS-Based Proteomics Services Market, by End User
9. NGS-Based Proteomics Services Market, by Geography
10. Competitive Landscape
11. Company Profiles
12. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Alamar Biosciences, Inc.
- Novogene Co., Ltd.
- Azenta, Inc.
